Cover

Dementia in Clinical Practice

Editor(s): Giannakopoulos P. (Geneva) 
Hof P.R. (New York, N.Y.) 
Table of Contents
Vol. 24, No. , 2009
Section title: Frontotemporal Dementia
Giannakopoulos P, Hof PR (eds): Dementia in Clinical Practice. Front Neurol Neurosci. Basel, Karger, 2009, vol 24, pp 168–178
(DOI:10.1159/000197896)

Frontotemporal Dementia: Therapeutic Interventions

Mendez M.F.
David Geffen School of Medicine at UCLA, and Neurobehavior V.A. Greater Los Angeles Healthcare System, Los Angeles, Calif., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

The management of frontotemporal dementia (FTD), a disorder characterized by varied behavioralsymptoms, primarily involves the use of psychoactive medications. Although there are no approvedtreatments for the disorder, selective serontonin receptor inhibitors, such as sertraline, paroxetine, orfluoxetine, can decrease disinhibition-impulsivity, repetitive behaviors, and eating disorders in FTD.Low doses of trazodone or an atypical antipsychotic such as aripriprazole can also help manage significantlydisturbed or agitated behavior. The acetylcholinesterase inhibitors used for patients withAlzheimer’s disease have not had significant efficacy for patients with FTD, but memantine, anotherdementia medication, is under investigation for the treatment of this disorder. In addition to drugtherapy, the nonpharmacological management of patients with FTD focuses on education, behavioralinterventions, and care of the caregivers. Most recently, investigators have initiated steps towardrational drug therapy with the development of outcome measures for clinical drug trials in FTD andthe characterization of treatment targets such tau protein or the TAR DNA-binding protein 43. Thisapproach holds great promise for an eventual treatment for this devastating early-onset dementia.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00